Vivus: Obesity Drug Data Satisfy Goals

Obesity-drug maker Vivus(VVUS Quote) reported results from a phase III study Thursday in which patients treated with a high dose of its experimental drug Qnexa lost 7.5% of their body weight adjusted for placebo.

The six-month, phase III "Equate" study treated more than 750 patients and compared two doses of Qnexa against the drug's individual components and a placebo.

Patients taking the high and low dose of Qnexa for six months reported an average 9.2% and 8.5% weight loss, respectively, compared to a 1.7% weight loss for patients on a placebo. Vivus said both Qnexa doses met the study's primary endpoint and were statistically significant. ...